Patients bearing tumors with high TMB, like melanoma and non-small-cell lung carcinoma (NSCLC), had higher ORRs to PD-1 and PD-L1 inhibition, whereas patients bearing tumors with lower TMB, such as Ewing sarcoma and prostate carcinoma, demonstrated fewer responses to ICB treatment. Here, CD274 is linked to non-small cell lung carcinoma.